Literature DB >> 11167991

Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.

D Flieger1, A S Hoff, T Sauerbruch, I G Schmidt-Wolf.   

Abstract

MoAbs against tumour-associated antigens (TAA) may be useful for the treatment of colorectal cancer. Since an increased expression of TAA may lead to enhanced antibody-dependent cellular cytotoxicity we examined whether the cytokines IL-2, IL-4, IL-6, IL-10, IL-12, interferon-alpha (IFN-alpha), IFN-gamma, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor and tumour necrosis factor-alpha can influence EpCAM and LewisY expression on the surface of the colorectal carcinoma cell lines HT29, LoVo and SW480. We found that only IFN-alpha increased significantly whereas IL-4 decreased both EpCAM and LewisY expression. IFN-gamma significantly increased LewisY expression only. When tumour cells were treated with MoAb, the LewisY-specific MoAb BR55-2 down-regulated LewisY antigen expression, whereas MoAb 17-1A, which binds to EpCAM, up-regulated this TAA after 3 days of culture. The cytokines IFN-alpha or IFN-gamma combined with MoAb 17-1A enhanced further slightly the expression of EpCAM. In additional experiments with chemotherapeutic drugs commonly used for the treatment of colorectal cancer, we found that 5-fluorouracil, mitomycin-C and oxaliplatin up-regulated EpCAM and LewisY antigen expression. Raltitrexed enhanced LewisY and down-regulated EpCAM expression, whereas CPT-11 had no influence at all. The highest expression for EpCAM on HT29 cells was achieved by the combination of IFN-alpha, 5-fluorouracil and MoAb 17-1A. Our results may be useful for defining combinations of biological and chemotherapeutic drugs for the treatment of colorectal cancer. Further trials should evaluate to what extent these combinations enhance antibody-dependent cellular cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11167991      PMCID: PMC1905949          DOI: 10.1046/j.1365-2249.2001.01435.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  53 in total

1.  The difference in pharmacokinetics of mitomycin C, given either as a single agent or as a part of combination chemotherapy.

Authors:  J Verweij; M Stuurman; J de Vries; H M Pinedo
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

2.  Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells.

Authors:  F Guadagni; J Schlom; W W Johnston; C A Szpak; D Goldstein; R Smalley; J F Simpson; E C Borden; S Pestka; J W Greiner
Journal:  J Natl Cancer Inst       Date:  1989-04-05       Impact factor: 13.506

3.  Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines.

Authors:  S Faivre; E Raymond; J M Woynarowski; E Cvitkovic
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

4.  Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity.

Authors:  G Masucci; P Wersäll; P Ragnhammar; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  The tumor-associated antigens BR55-2, GA73-3 and GICA 19-9 in normal and corresponding neoplastic human tissues, especially gastrointestinal tissues.

Authors:  J Shetye; B Christensson; C Rubio; M Rodensjö; P Biberfeld; H Mellstedt
Journal:  Anticancer Res       Date:  1989 Mar-Apr       Impact factor: 2.480

6.  Selective chromosomal damage and cytotoxicity of 125I-labeled monoclonal antibody 17-1a in human cancer cells.

Authors:  D V Woo; D Li; J A Mattis; Z Steplewski
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

7.  Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma.

Authors:  D H Munn; N K Cheung
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

8.  Abnormal blood monocytes in chronic lymphocytic leukemia.

Authors:  D Flieger; H W Ziegler-Heitbrock
Journal:  Cancer Res       Date:  1988-09-01       Impact factor: 12.701

9.  Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies.

Authors:  J R Ortaldo; C Woodhouse; A C Morgan; R B Herberman; D A Cheresh; R Reisfeld
Journal:  J Immunol       Date:  1987-05-15       Impact factor: 5.422

10.  Role of interleukin 2, interleukin 4, and alpha, beta, and gamma interferon in stimulating macrophage antibody-dependent tumoricidal activity.

Authors:  P Ralph; I Nakoinz; D Rennick
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

View more
  13 in total

1.  H-Type 1 carbohydrate antigen expression by ovine endometrial cells.

Authors:  S Woldesenbet; T Green; G R Newton
Journal:  In Vitro Cell Dev Biol Anim       Date:  2002-06       Impact factor: 2.416

Review 2.  Chemotherapy and Physical Therapeutics Modulate Antigens on Cancer Cells.

Authors:  Wojciech Szlasa; Natalia Janicka; Natalia Sauer; Olga Michel; Bernadetta Nowak; Jolanta Saczko; Julita Kulbacka
Journal:  Front Immunol       Date:  2022-07-06       Impact factor: 8.786

3.  The study of chemiluminescence in gastric and colonic carcinoma cell lines treated by anti-tumor drugs.

Authors:  Che Chen; Fu-Kun Liu; Xiao-Ping Qi; Jie-Shou Li
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

4.  A rare-cell detector for cancer.

Authors:  Robert T Krivacic; Andras Ladanyi; Douglas N Curry; H B Hsieh; Peter Kuhn; Danielle E Bergsrud; Jane F Kepros; Todd Barbera; Michael Y Ho; Lan Bo Chen; Richard A Lerner; Richard H Bruce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

5.  Interferon-gamma reduces cell surface expression of annexin 2 and suppresses the invasive capacity of prostate cancer cells.

Authors:  Claire Hastie; John R Masters; Stephen E Moss; Soren Naaby-Hansen
Journal:  J Biol Chem       Date:  2008-01-22       Impact factor: 5.157

Review 6.  Altered glycosylation in inflammatory bowel disease: a possible role in cancer development.

Authors:  B J Campbell; L G Yu; J M Rhodes
Journal:  Glycoconj J       Date:  2001 Nov-Dec       Impact factor: 2.916

Review 7.  Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule.

Authors:  Monika Trzpis; Pamela M J McLaughlin; Lou M F H de Leij; Martin C Harmsen
Journal:  Am J Pathol       Date:  2007-06-28       Impact factor: 4.307

8.  High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas.

Authors:  Zahra Madjd; Tina Parsons; Nicholas F S Watson; Ian Spendlove; Ian Ellis; Lindy G Durrant
Journal:  Breast Cancer Res       Date:  2005-07-28       Impact factor: 6.466

9.  Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.

Authors:  P Went; M Vasei; L Bubendorf; L Terracciano; L Tornillo; U Riede; J Kononen; R Simon; G Sauter; P A Baeuerle
Journal:  Br J Cancer       Date:  2006-01-16       Impact factor: 7.640

10.  Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival.

Authors:  G Spizzo; G Gastl; D Wolf; E Gunsilius; M Steurer; D Fong; A Amberger; R Margreiter; P Obrist
Journal:  Br J Cancer       Date:  2003-02-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.